MovDisordV3, PascalFrancis, Curation, bibRecord, 002F07

Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease

Identifieur interne : 002F07 ( PascalFrancis/Curation ); précédent : 002F06; suivant : 002F08

Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease

Auteurs : J. Vaamonde ; M. R. Luquin ; J. A. Obeso

Source :

Movement disorders [ 0885-3185 ] ; 1990.

RBID : Pascal:91-0247282

Descripteurs français

Pascal (Inist)
- Stimulant dopaminergique, Association médicamenteuse, Tolérance, Homme, Système nerveux pathologie, Encéphale, Lisuride, Dopa, Régulation, Récepteur dopaminergique, Corps strié, Parkinson maladie, Maladie dégénérative, Transmission dopaminergique, Antiparkinsonien.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Brain, Corpus striatum, Degenerative disease, Dopa, Dopamine agonist, Dopamine receptor, Dopaminergic transmission, Drug combination, Human, Nervous system diseases, Parkinson disease, Regulation(control), Tolerance.

Abstract

The aim of this study was to assess whether or not continuous infusion of lisuride in combination with intermittent levodopa-carbidopa administration was associated with tolerance. Intravenous apomorphine was given to four patients before initiation of chronic treatment with subcutaneous lisuride infusion and oral levodopa. The study was repeated under identical conditions after a mean of 18 months of treatment

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 5`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease`
A11	`01`	`1`		`@1 VAAMONDE (J.)`
A11	`02`	`1`		`@1 LUQUIN (M. R.)`
A11	`03`	`1`		`@1 OBESO (J. A.)`
A14	`01`			`@1 Univ. Navarra, clin. univ., dep. neurology @2 Pamplona 31080 @3 ESP @Z A11011000`
A20				`@1 260-262`
A21				`@1 1990`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @3 354000004800050150`
A44				`@0 0000`
A45				`@0 11 ref.`
A47	`01`	`1`		`@0 91-0247282`
A60				`@1 P`
A61				`@0 A`
A64		`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 The aim of this study was to assess whether or not continuous infusion of lisuride in combination with intermittent levodopa-carbidopa administration was associated with tolerance. Intravenous apomorphine was given to four patients before initiation of chronic treatment with subcutaneous lisuride infusion and oral levodopa. The study was repeated under identical conditions after a mean of 18 months of treatment`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Stimulant dopaminergique`
C03	`02`	`X`	`FRE`	`@0 Association médicamenteuse`
C03	`03`	`X`	`FRE`	`@0 Tolérance`
C03	`04`	`X`	`FRE`	`@0 Homme`
C03	`05`	`X`	`FRE`	`@0 Système nerveux pathologie`
C03	`06`	`X`	`FRE`	`@0 Encéphale`
C03	`07`	`X`	`FRE`	`@0 Lisuride`
C03	`08`	`X`	`FRE`	`@0 Dopa`
C03	`09`	`X`	`FRE`	`@0 Régulation`
C03	`10`	`X`	`FRE`	`@0 Récepteur dopaminergique`
C03	`11`	`X`	`FRE`	`@0 Corps strié`
C03	`12`	`X`	`FRE`	`@0 Parkinson maladie`
C03	`13`	`X`	`FRE`	`@0 Maladie dégénérative`
C03	`14`	`X`	`FRE`	`@0 Transmission dopaminergique`
C03	`15`	`X`	`FRE`	`@0 Antiparkinsonien`
C03	`01`	`X`	`ENG`	`@0 Dopamine agonist`
C03	`02`	`X`	`ENG`	`@0 Drug combination`
C03	`03`	`X`	`ENG`	`@0 Tolerance`
C03	`04`	`X`	`ENG`	`@0 Human`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases`
C03	`06`	`X`	`ENG`	`@0 Brain`
C03	`08`	`X`	`ENG`	`@0 Dopa`
C03	`09`	`X`	`ENG`	`@0 Regulation(control)`
C03	`10`	`X`	`ENG`	`@0 Dopamine receptor`
C03	`11`	`X`	`ENG`	`@0 Corpus striatum`
C03	`12`	`X`	`ENG`	`@0 Parkinson disease`
C03	`13`	`X`	`ENG`	`@0 Degenerative disease`
C03	`14`	`X`	`ENG`	`@0 Dopaminergic transmission`
C03	`15`	`X`	`ENG`	`@0 Antiparkinson agent`
C03	`01`	`X`	`SPA`	`@0 Estimulante dopaminérgico`
C03	`02`	`X`	`SPA`	`@0 Asociación medicamentosa`
C03	`03`	`X`	`SPA`	`@0 Tolerancia`
C03	`04`	`X`	`SPA`	`@0 Hombre`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología`
C03	`06`	`X`	`SPA`	`@0 Encéfalo`
C03	`08`	`X`	`SPA`	`@0 Dopa`
C03	`09`	`X`	`SPA`	`@0 Regulación`
C03	`10`	`X`	`SPA`	`@0 Receptor dopaminérgico`
C03	`11`	`X`	`SPA`	`@0 Cuerpo estriado`
C03	`12`	`X`	`SPA`	`@0 Parkinson enfermedad`
C03	`13`	`X`	`SPA`	`@0 Enfermedad degenerativa`
C03	`14`	`X`	`SPA`	`@0 Transmisión dopaminérgica`
C03	`15`	`X`	`SPA`	`@0 Antiparkinsoniano`
N21				`@1 036`
N82				`@1 NIM`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003918

Links to Exploration step

Pascal:91-0247282

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease</title>
<author><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J." last="Vaamonde">J. Vaamonde</name>
</author>
<author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name>
</author>
<author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J. A." last="Obeso">J. A. Obeso</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">91-0247282</idno>
<date when="1990">1990</date>
<idno type="stanalyst">PASCAL 91-0247282 INIST</idno>
<idno type="RBID">Pascal:91-0247282</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003918</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002F07</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease</title>
<author><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J." last="Vaamonde">J. Vaamonde</name>
</author>
<author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name>
</author>
<author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J. A." last="Obeso">J. A. Obeso</name>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1990">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Brain</term>
<term>Corpus striatum</term>
<term>Degenerative disease</term>
<term>Dopa</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Dopaminergic transmission</term>
<term>Drug combination</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Regulation(control)</term>
<term>Tolerance</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Stimulant dopaminergique</term>
<term>Association médicamenteuse</term>
<term>Tolérance</term>
<term>Homme</term>
<term>Système nerveux pathologie</term>
<term>Encéphale</term>
<term>Lisuride</term>
<term>Dopa</term>
<term>Régulation</term>
<term>Récepteur dopaminergique</term>
<term>Corps strié</term>
<term>Parkinson maladie</term>
<term>Maladie dégénérative</term>
<term>Transmission dopaminergique</term>
<term>Antiparkinsonien</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this study was to assess whether or not continuous infusion of lisuride in combination with intermittent levodopa-carbidopa administration was associated with tolerance. Intravenous apomorphine was given to four patients before initiation of chronic treatment with subcutaneous lisuride infusion and oral levodopa. The study was repeated under identical conditions after a mean of 18 months of treatment</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>5</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VAAMONDE (J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LUQUIN (M. R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>OBESO (J. A.)</s1>
</fA11>
<fA14 i1="01"><s1>Univ. Navarra, clin. univ., dep. neurology</s1>
<s2>Pamplona 31080</s2>
<s3>ESP</s3>
<sZ>A11011000</sZ>
</fA14>
<fA20><s1>260-262</s1>
</fA20>
<fA21><s1>1990</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s3>354000004800050150</s3>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>11 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>91-0247282</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The aim of this study was to assess whether or not continuous infusion of lisuride in combination with intermittent levodopa-carbidopa administration was associated with tolerance. Intravenous apomorphine was given to four patients before initiation of chronic treatment with subcutaneous lisuride infusion and oral levodopa. The study was repeated under identical conditions after a mean of 18 months of treatment</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tolérance</s0>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Encéphale</s0>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lisuride</s0>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Dopa</s0>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Régulation</s0>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Corps strié</s0>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Parkinson maladie</s0>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Transmission dopaminergique</s0>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dopamine agonist</s0>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Drug combination</s0>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Tolerance</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Brain</s0>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Dopa</s0>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Regulation(control)</s0>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Dopamine receptor</s0>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Corpus striatum</s0>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Parkinson disease</s0>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Degenerative disease</s0>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Dopaminergic transmission</s0>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tolerancia</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Encéfalo</s0>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Dopa</s0>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Regulación</s0>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Cuerpo estriado</s0>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Transmisión dopaminérgica</s0>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
</fC03>
<fN21><s1>036</s1>
</fN21>
<fN82><s1>NIM</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F07 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002F07 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:91-0247282
   |texte=   Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease

Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri